Category: Arm

  • Noisy activists aside, GSK investors backed Walmsley and her strategy

    The ‘step-change’ in growth for the core pharma division has barely started, but the CEO is secure for now Emma Walmsley is at the starting line. That may sound a churlish assessment of years of graft to get GlaxoSmithKline’s consumer products division fit for demerger this summer, but it’s roughly accurate. The “step-change in growth”, […]